Patent 12005127 was granted and assigned to Vertex Pharmaceuticals on June, 2024 by the United States Patent and Trademark Office.
The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions, or disorders.